35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...

GSK to buy 35Pharma for $950 million in CEO Miel's second major deal

Feb 25 (Reuters) - GSK has agreed to pay $950 million in cash for Canadian biotech 35Pharma, it said on Wednesday, marking ...
pharmaphorum

GSK grows pipeline with 35Pharma takeover, Frontier deal

35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...

GSK inks licensing deal worth up to $1B with China’s Frontier Bio

GSK (GSK) stock is in focus as the company inks a drug licensing deal worth up to $1B with China's Frontier Biotechnologies for siRNA treatments. Read more here.

Frontier Biotech and GSK Enter Global Exclusive Licensing Agreement for Small Interfering RNA Therapeutics

"We are excited to establish the agreement with GSK, a global biopharma company. It reflects the growing recognition of our R&D capabilities. This agreement will solidify a robust foundation for ...
PharmTech

GSK in Agreement to Acquire 35Pharma for Nearly $1B

GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...

GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play

GSK plc (NSE: GSK) on Wednesday agreed to acquire 35Pharma Inc. for $950 million. 35Pharma is a Canada-based, private, ...
Pharmaceutical Technology

GSK continues dealmaking spree with $950m 35Pharma acquisition

The 35Pharma acquisition comes as GSK looks to stock up its pipeline amid the looming patent expiries soon to impact its ...